Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 8,785 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $31.29, for a total value of $274,882.65. Following the completion of the sale, the general counsel owned 15,809 shares in the company, valued at approximately $494,663.61. This represents a 35.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jonathan Allan also recently made the following trade(s):

• On Thursday, December 4th, Jonathan Allan sold 1,018 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total transaction of $31,425.66.
• On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.65, for a total transaction of $70,249.80.
• On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $68,017.52.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $250,700.00.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded down $0.18 during trading on Friday, hitting $30.87. 602,753 shares of the company’s stock were exchanged, compared to its average volume of 917,923. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 46.07 and a beta of 1.14. The business has a 50-day simple moving average of $28.90 and a 200-day simple moving average of $19.69. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, equities analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on STOK. Wedbush raised their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Needham & Company LLC raised their price target on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and an average price target of $31.00.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in STOK. CANADA LIFE ASSURANCE Co raised its position in Stoke Therapeutics by 12.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after acquiring an additional 1,313 shares during the period. Polar Capital Holdings Plc grew its position in shares of Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after purchasing an additional 439,824 shares during the period. Parkman Healthcare Partners LLC purchased a new stake in shares of Stoke Therapeutics during the third quarter worth about $5,875,000. Nomura Holdings Inc. acquired a new position in shares of Stoke Therapeutics during the 3rd quarter worth about $1,908,000. Finally, Millennium Management LLC raised its position in shares of Stoke Therapeutics by 199.3% during the 3rd quarter. Millennium Management LLC now owns 61,048 shares of the company’s stock worth $1,435,000 after purchasing an additional 40,652 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.